Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase
The LIBERTY-CD study demonstrated superior efficacy of subcutaneous infliximab-dyyb over placebo for maintenance therapy in patients with Crohn's disease. This post hoc analysis characterised subgroups of patients with different response levels to subcutaneous infliximab. Gr
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.